Integrating Brain, Neurocognitive, and Computational Tools in Opioid Use Disorder (OUD) to Characterize Executive Function and to Predict Clinical Outcomes
Recruiting
18 years - 60 years
All
Phase
3
192 participants needed
1 Location
Brief description of study
The 5-year K01 Mentored Research Scientist proposal will
employ brain, neurocognitive, and computational tools (e.g., machine learning)
to understand the impact of opioid-use disorder (OUD) and common co-occurring
issues on executive function and clinical outcomes.
Detailed description of study
The 5-year K01 Mentored Research Scientist proposal will
employ brain, neurocognitive, and computational tools to understand the impact
of opioid-use disorder (OUD) and common co-occurring issues on executive
function and clinical outcomes. There have been record numbers of fatal and
non-fatal overdoses (ODs) associated with opioids (and other drugs) in the past
12-months. Improving classification and predictive capabilities to enhance
treatment and prevent relapse is of the upmost importance. Deficits in
neurocognition often are associated with poor treatment outcomes (e.g., more
drug use, medication non-adherence), yet co-occurring issues associated with
OUD (e.g., depression, anxiety, physical/sexual abuse, neglect) make it
difficult to parse which contributing factors lead to worse executive function
(EF) and poorer treatment outcomes. Novel brain, neurocognitive, and
computational tools are needed to help determine these differences, in order to
lay the foundation for better treatments. This need has shaped both the
training plan and the associated research project in a 5-year K01 Mentored
Research Scientist proposal, building on Dr. Regier's prior preclinical and
clinical addiction neuroscience experience (focused mostly on cocaine-use
disorders, cue-reactivity, subcortical networks, prior adversity, and
univariate imaging techniques)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Opioid use disorder,Healthy controls
-
Age: 18 years - 60 years
-
Gender: All
Inclusion
- Men and women with moderate to severe opioid use disorder by DSM-V criteria on a stable (at least one week without change) dose of any buprenorphine-naloxone or methadone.
- Eligible participants will be between the ages of 18-60 years; able to read at an eighth-grade level; and able to speak English
Exclusion
- Unable to understand or complete the tasks; this includes inability to understand or complete tasks due to intoxication, English language deficits, etc.
- Certain mental health conditions determined by the PI to interfere with study participation.
Updated on
30 Jun 2025.
Study ID: 23-1237
Pre-Screener
Interested in the study
Select a study center that’s convenient for you, and get in touch with the study team.
Contact a study centerPlease choose between Voice or SMS based delivery of verification code
or